Fasenra

Active Ingredient(s): Benralizumab
FDA Approved: * November 14, 2017
Pharm Company: * ASTRAZENECA AB
Category: Asthma

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody medication which is developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[2][3] Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.[4][5] It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe e... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Fasenra 30 mg/ml Subcutaneous Injection, Solution

NDC: 0310-1730

Labeler:

Astrazeneca Pharmaceuticals Lp

Fasenra 30 mg/ml Subcutaneous Injection, Solution

NDC: 0310-1830

Labeler:

Astrazeneca Pharmaceuticals Lp